Report
Valens Research

AGN - Embedded Expectations Analysis - 2019 02 20

Allergan plc (AGN:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 7.2x Uniform P/E, implying bearish expectations for the firm. Meanwhile, management may have concerns about core business growth, competitive pressures on BOTOX, and their Medical Aesthetics pipeline

Specifically, management may lack confidence in their ability to sustain revenue growth in their core businesses and reverse international sales declines. Additionally, they may be understating competitive pricing pressures on BOTOX, and may be concerned about the ability of migraine treatments to coexist with BOTOX and about long-term BOTOX sales. Moreover, they may be exaggerating the strength of their Medical Aesthetics pipeline, and the buying power of millennials
Underlying
Allergan plc

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch